Abstract Several functionally distinct isoforms of the actin regulatory Mena are produced by alternative splicing during tumor progression. 
Introduction
While metastasis remains the leading cause of death in cancer patients, the molecular mechanisms driving this process are incompletely understood. Changes within the primary tumor itself or in the microenvironment can lead to local invasion and ultimately metastasis. For example, during the epithelial to mesenchymal transition (EMT), cells can undergo changes in gene expression which endow carcinoma cells with aggressive, metastatic characteristics [1] . Increased matrix stiffening, collagen crosslinking and integrin-dependent focal adhesion are also associated with breast tumorigenesis and can promote progression to an invasive and metastatic phenotype [2, 3] . Hypoxia, via stabilization of hypoxia-inducible factor (HIF1a), regulates the expression of multiple genes that can lead to changes in anaerobic metabolism, angiogenesis, invasion and survival [4] . Finally, the tumor stroma plays an important role in promoting metastasis as recruitment of macrophages or bone marrow derived cells to the primary tumor site can increase cell migration, invasion and intravasation [5] .
Mena, a member of the Ena/VASP family, is a known regulator of actin polymerization and cell:matrix, and cell: adhesion that is upregulated in various human epithelial tumors, including breast, pancreas, lung, colon and cervix [6] . In the MMTV-PyMT genetic model of breast cancer, genetic ablation of Mena significantly reduces in vivo tumor cell motility, intravasation and metastasis without altering mammary tumor burden, growth or histologic progression to carcinoma [7] . Mena-expressing cells are components of tumor microenvironment of metastasis (TMEM), tripartite structures comprised of a Mena-expressing tumor cell, an endothelial cell and a macrophage all contacting each other. TMEMs are sites of intravasation in mouse mammary tumors [8] , and TMEM density correlates with risk of distant metastasis in ER-/HER2? breast cancer patients [9, 10] .
During tumor progression, Mena is alternatively spliced to produce multiple isoforms that can affect tumor cell phenotypes in different ways [6] . Expression of Mena11a, an isoform of Mena that contains an additional 21 amino acids in the EVH2 domain of Mena, is highly expressed in primary tumor cells, but downregulated in invasive cells [11] , and has been shown to decrease motility in vivo and dampen invasion responses to EGF [12] . In two patient cohorts, quantitative immunofluorescence of a biomarker Mena calc derived from the difference in expression levels of all Mena isoforms (''panMena'') and Mena11a showed that high Mena calc levels are associated with poor diseasespecific survival [13, 14] .
Conversely, inclusion of the 19-amino acid sequence encoded by the 'INV' exon ( Fig. 1a) in Mena promotes invasion, intravasation and metastasis by sensitizing cells to EGF, subsequently allowing them to invade in response to low concentrations of growth factor [12, 15] . Notably, the lack of a sensitive isoform-specific antibody capable of detecting Mena INV in tumors has necessitated use of RT-PCR analysis of mRNA isolated from dissociated tumor tissues as a proxy for the protein. Using xenograft and spontaneous breast tumor models, we found that expression of Mena INV mRNA is comparatively high in invasive cells collected by EGF chemotaxis from the primary tumor [11] . Furthermore, in cells isolated from fine needle aspirates (FNA) of breast human tumors, Mena INV mRNA levels were relatively higher in the subset of tumor cells that had traversed a human endothelial cell monolayer in in vitro intravasation assays [16] . Finally, in human breast cancer patients, relative levels Mena INV mRNA in FNA biopsies from freshly resected breast tumor samples were observed to correlate with the number of TMEM sites found histological sections from the matched tumor tissue [16, 17] [18] (Fig. 1a) . Anti-INV recognized GFP-Mena INV -but not GFP-Mena or GFP alone-in western blots of lysates of MDA-MB231 cells that express the corresponding constructs. Anti-panMena, which recognizes all known Mena isoforms [19] , detected ectopic GFP-Mena, GFPMena INV and endogenous Mena (Fig. 1b) . We developed an ELISA assay to detect and to quantify Mena INV levels in protein lysates. We confirmed the specificity of the ELISA assay using two peptides expressing either EVH1-LERER or EVH1-INV-LERER. Increasing the concentration of the EVH1-INV-LERER peptide correlated with an increase in signal as detected by the ELISA assay, while no signal was detected with the EVH1-LERER peptide (Fig. 1c) (Fig. 1d) . Together, these data confirmed the specificity of the antibody and quantitative nature of the ELISA assay.
Given that we have shown that at the mRNA level, Mena INV expression is enriched in invasive cell populations of xenograft tumors, PyMT tumors [21] , and in FNA biopsies of human breast tumors [16] , we were interested in We then studied the relationship between Mena and Mena INV expression during tumor progression in the MMTV-PyMT model [22] . Overall, we observed heterogeneous Mena INV staining in subsets of Mena-expressing cells in MMTV-PyMT tumors (Fig. 2e) . Specifically, there were significant increases in both Mena and Mena INV staining in both adenoma and carcinoma tumor regions relative to hyperplasia (Fig. 2f, g ). Together, these data suggest that in the MMTV-PyMT model Mena and Mena INV expression increases during progression from hyperplasia to adenoma, with no further increases during progression to carcinoma.
Next, we examined Mena and Mena INV protein expression and localization in a small cohort of both metastatic and non-metastatic human breast tumors (tumor characteristics described in Fig S1) . We found that while Mena is expressed at high levels in ductal structures in nonmetastatic tumors (Fig. 3a-c) only low levels of Mena INV were detected. As shown in the PyMT mouse model, we found robust levels of Mena INV in structures characterized as ductal carcinoma in situ (DCIS), which are known to contain an intact basement membrane (Fig. 3d-f (Fig. 3j) , as well as increased levels of Mena INV , as detected by quantitative immunofluorescence (Fig. 3l) . Levels of Mena were not significantly different between non-metastatic and metastatic cases (Fig. 3k) . Overall, these data demonstrate that Mena INV expression increases during tumor progression in both mouse and human tumors.
Mena INV is not expressed in macrophages, endothelial cells or fibroblasts
The tumor microenvironment is composed of a variety of tumor and stromal cells, which can also contribute to tumor progression [5] . We were interested in investigating whether Mena INV was expressed in endothelial cells, macrophages and fibroblasts within tumors. We used established markers to stain for all three subpopulations in PyMT tumors: Iba1 for macrophages (Fig. 4a) ; aSMA (smooth muscle actin) for fibroblasts (Fig. 4b) ; CD31 for endothelial cells (Fig. 4c) . We did not detect Mena INV signal in any of the cells expressing these markers and conclude that Mena INV is either absent or expressed at low levels in these stromal subtypes.
Mena

INV expression is not restricted to cells that have undergone EMT
To characterize the identity of the cells that express Mena INV in the tumor compartment, we compared the distribution of anti-INV staining to markers of tumor cell phenotype. First, we wondered if expression of Mena INV was associated with EMT, a process that has been associated with increased metastatic potential [23] . Antibodies to E-Cadherin and vimentin, markers for epithelial and mesenchymal phenotypes respectively, were used to examine levels of Mena INV varied throughout mouse and human tumors in relation to EMT. Line scans of the signal intensities showed regions that appeared to have relatively high Mena INV and low E-cadherin signals (Fig. 5a ). Quantitative analysis throughout entire image fields revealed a significant, inverse correlation between relative levels of Mena INV and of E-cadherin (Fig. 5b, c 
Mena
INV expression is not enriched with cells expressing proliferation and stem cell markers
More recently, EMT has been associated with the gain of stem cell characteristics, which endow cells with the ability to metastasize and colonize more efficiently [24] . We (Fig. 6a) (Fig. 6b, c) . These data suggest that Mena INV expression is not restricted to highly proliferative cells. Secondly, we examined Mena INV expression relative to two known stem cell markers in mouse PyMT tumors, ALDH and CD133, whose expression has been associated with stemness (Fig. 6d) . Indeed, recent studies have shown that cells expressing high levels of CD133 showed higher invasive potential and drug resistance, while cells that were ALDH-and CD133-positive were highly tumorigenic [25] [26] [27] . As expected, we observed a positive correlation between CD133 and ALDH expression (Fig. 6e) (Fig. 6f, h) (Fig. 6f, h ). These data indicate that Mena INV is expressed in both stem and non-stem cell populations within advanced tumors. We compared Mena INV and CD133 or ALDH staining intensity in different regions of PyMT tumors and observed no significant correlation between Mena INV signal and the levels of these stem cell markers.
Mena INV expression is high in vascularized tumor areas
Dissemination of primary tumor cells occurs primarily through the vasculature and lymphatics. We examined patterns of Mena INV expression relative to blood vessels in mouse and human tumors. In both mouse and human tumors, we found that Mena INV expression was not restricted to cells adjacent to blood vessels (Fig. 7a, b) . However, there was a significant correlation between Mena INV expression levels and blood vessel density in both non-metastatic and metastatic human tumors (Fig. 7c) . Together, these data confirm that while Mena INV expression is associated with higher blood vessel density, it is not restricted to expression in cells adjacent to the vasculature.
Blood vessel density can also affect oxygen levels within a tumor, which in turn, can drive metastatic phenotypes. Using hypoxyprobe to label hypoxic tumor areas [28] , we quantified Mena INV staining intensity in PyMT-MMTV tumors relative to hypoxia (Fig. 7d, e) and determined that Mena INV expression was not restricted to hypoxic areas within the tumor. 
Discussion
The data presented here provide the first characterization of endogenous Mena INV protein expression in mouse breast cancer models and in human invasive ductal carcinomas. Our studies reveal that expression of Mena INV is heterogeneously distributed in tumors and that Mena INV expression can be detected in early tumors with increasing levels during early tumor progression. Our comparison of Mena INV staining to the distributions of well-established markers provides insight into the nature of the tumor cells that express Mena INV . We developed a Mena INV isoform-specific monoclonal antibody, and demonstrated its specificity and functionality in ELISA and Western blot assays, and for immunodetection of endogenously expressed protein in human and mouse sections of FFPE tumor tissue. Our analysis provides important information on the propoerties of cells that express Mena INV , allowing us to gain further insight into the potential mechanisms by which it drives metastasis. We it is likely restricted to the tumor compartment. Finally, we show that while expression of Mena INV is high in areas of high blood vessel density, it is heterogeneous within the primary tumor and not confined to cells adjacent to blood vessels. In fact, Mena INV expression can also be detected in non-(or perhaps pre-) invasive tumor compartments with an intact basement membrane, suggesting that Mena INV is expressed early during breast cancer progression and in multiple locations. Together, these data suggest the role of
Mena
INV in promoting invasion and metastasis is not restricted to a role only in perivascular tumor cells at sites of intravasation, like those found in TMEM. This finding is consistent with our previous work showing that Mena INV promotes matrix degradation, paracrine signaling with macrophages, discohesive tumor morphology and increased tumor cell motility [12, 15, 29] . As recent work demonstrates that the Mena-expressing tumor cell in TMEM is relatively stable [8] , it will be interesting to figure online) determine whether and how Mena
Mouse models
All animal experiments were approved by the MIT Division of Comparative Medicine. PyMT-MMTV mice at 12 weeks of age were injected with 10 mg/kg Hypoxyprobe 1 h before sacrifice. To detect hypoxic areas, we used the Hypoxyprobe kit according to the manufacturer's protocol [28] . We injected 60 mg/kg of Piminidazole-HCl IP 1 h before sacrificing mice. Signal was then detected by immunostaining. Dissected tumors were dissociated using lysis buffer (see below) and mortar and pestle.
Western blotting
MDAMB231 expressing different Mena isoforms were lysed in 25 mM Tris, 150 mM NaCl, 10 % glycerol, 1 % NP 40 and 0.5 M EDTA with a protease Mini-complete protease inhibitors (Roche) and a phosphatase inhibitor cocktail (PhosSTOP, Roche) at 4°C. Protein lysates were separated by SDS-PAGE, transferred to a nitrocellulose membrane, blocked with Odyssey Blocking Buffer (LiCor), incubated in primary antibody overnight at 4°C. Proteins were detected using Licor secondary antibodies.
Immunostaining
Tumors from MMTV-PyMT mice were fixed in 10 % buffered formalin and embedded in paraffin. Sections from FFPE human breast cancer tumors were obtained from Dr. Joan Jones. Tissue sections (5 lm thick) were deparaffinized followed by antigen retrieval using Citra Plus solution (Biogenex). After treatment with 3 % H 2 O 2 , sections were blocked with serum and incubated with primary antibodies overnight at 4°C. Fluorescently labeled secondary antibodies were added at 25°C for 2 h. For detection of Mena INV in FFPE sections, the INV antibody was biotinylated, followed by amplification with streptavidin-horseradish peroxidase, tyramide-biotin amplification (Perkin Elmer), and detection with a fluorescently tagged streptavidin antibody. Serial Z series image stacks were collected using a DeltaVision microscope controlled by Softworx software (GE Health) with a 40 9 1.3 NA plan-apo objective and deconvolved using Softworx. Images were then analyzed using ImageJ.
Image analysis
For Fig. 2 , images within each panel were taken with the same settings and can be compared. However, panels a, d, e cannot be directly compared for intensity readings. Tumor area was delimited using DAPI staining, and intensity of signal was measured in each field of view using ImageJ. For Fig. 3 , all images were acquired simultaneously and intensity can be compared within the figure. For Figs. 3g,  5d , 6a-d, f, h, analysis of expression of markers was done on a per cell basis in multiple fields of view from multiple tissue samples. The number of positive cells for a specific marker was made relative to the total number of DAPIpositive cells in the field of view. For Fig. 5 , custom written Matlab scripts were used for image analysis of ECadherin levels. For Fig. 7 , blood vessel density was quantified using ImageJ, quantifying the area covered by blood vessels as marked by CD31 staining relative to the area of the field of view.
